Menu hamburgerclose
Sciences & Technology

Zytoprotec’s unique therapeutic approach

Our ground-breaking research on biomarkers in peritoneal dialysis is directly contributing to the design of an efficient yet scientifically sound pivotal Phase III trial with PDprotec® that we are currently preparing, and will support the eventual market approval process.

We are collaborating with partners in world-class research bodies and institutions.

During evolution, cells of all species have developed and optimized a powerful mechanism to protect against stress. Every clinically relevant insult therefore not only causes cellular injury but also activates the cellular stress response (Cytoprotection).

However, this mechanism is inhibited in certain diseases or when substances are applied that are “new” from an evolution biology, such as PD solutions.

Research conducted by Zytoprotec has shown that the protective mechanism of cells can be restored by intervention with cytoprotective compounds.

This offers the potential to prevent cells, tissues and whole organs from damage, thereby improving the quality of live and the survival of patients.

With PDprotec®, Zytoprotec is applying this new approach to the area of renal replacement therapy.

Our science

The development of PDprotec® has led to numerous publications and presentations in medical and scientific journals as well as professional and scientific meetings ever since. Our researchers have not only been publishing in leading journals but also been receiving prestigious awards and prizes in their fields.

Key publications directly related to PDprotec®

Grunert, T., R. Herzog, F.M. Wiesenhofer, A. Vychytil, M. Ehling-Schulz, and K. Kratochwill, Vibrational Spectroscopy of Peritoneal Dialysis Effluent for Rapid Assessment of Patient CharacteristicsBiomolecules, 2020. 10(6)  |

Bartosova, M., R. Herzog, D. Ridinger, E. Levai, H. Jenei, C. Zhang, G.T. González Mateo, I. Marinovic, T. Hackert, F. Bestvater, M. Hausmann, M. López Cabrera, K. Kratochwill, S.G. Zarogiannis, and C.P. Schmitt, Alanyl-Glutamine Restores Tight Junction Organization after Disruption by a Conventional Peritoneal Dialysis Fluid. Biomolecules, 2020.10(8)  |

Boehm, M., J. Niewczas, H. Herkner, F. Koenig, K. Kratochwill, P. Rutherford, C. Aufricht, and A. Vychytil, Composite Outcome Improves Feasibility of Clinical Trials in Peritoneal Dialysis. Perit Dial Int, 2019. 39(5): p. 479-485  |

Boehm, M., R. Herzog, F. Klinglmuller, A.M. Lichtenauer, A. Wagner, M. Unterwurzacher, R.H.J. Beelen, S.L. Alper, C. Aufricht, and K. Kratochwill, The Peritoneal Surface Proteome in a Model of Chronic Peritoneal Dialysis Reveals Mechanisms of Membrane Damage and Preservation. Front Physiol, 2019. 10: p. 472  |

Wiesenhofer, F.M., R. Herzog, M. Boehm, A. Wagner, M. Unterwurzacher, D.C. Kasper, S.L. Alper, A. Vychytil, C. Aufricht, and K. Kratochwill, Targeted Metabolomic Profiling of Peritoneal Dialysis Effluents Shows Anti-oxidative Capacity of Alanyl-Glutamine. Front Physiol, 2018. 9(1961): p. 1961  |

Vychytil, A., R. Herzog, P. Probst, W. Ribitsch, K. Lhotta, V. Machold-Fabrizii, M. Wiesholzer, M. Kaufmann, H. Salmhofer, M. Windpessl, A.R. Rosenkranz, R. Oberbauer, F. Konig, K. Kratochwill, and C. Aufricht, A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int, 2018. 94(6): p. 1227-1237  |

Herzog, R., M. Boehm, M. Unterwurzacher, A. Wagner, K. Parapatics, P. Majek, A.C. Mueller, A. Lichtenauer, K.L. Bennett, S.L. Alper, A. Vychytil, C. Aufricht, and K. Kratochwill, Effects of Alanyl-Glutamine Treatment on the Peritoneal Dialysis Effluent Proteome Reveal Pathomechanism-Associated Molecular Signatures. Mol Cell Proteomics, 2018. 17(3): p. 516-532  |

Herzog, R., L. Kuster, J. Becker, T. Gluexam, D. Pils, A. Spittler, M.K. Bhasin, S.L. Alper, A. Vychytil, C. Aufricht, and K. Kratochwill, Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid. Sci Rep, 2017. 7(1): p. 6229  |

Intellectual Property

2008, Zytoprotec filed for an international patent for glucose based peritoneal dialysis fluid containing alanyl-glutamine dipeptide, the active cytoprotective compound in PDprotec®.
The patent specification was published early in 2012 and the patent was granted for Europe on 23 October 2012. In addition, patent protection exists in Canada, Hong Kong and Japan, while in the U.S.A. the granting process is not yet entirely finished. For ICOprotec®, EU and PCT applications have been made. We went into the national phases in 2014.